about
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trialsInterleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusCause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFCan one assess whether missing data are missing at random in medical studies?Mobile cardiac catheterization laboratories increase use of cardiac care in women and African Americans.Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?Challenges and solutions to pre- and post-randomization subgroup analyses.Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarctionInference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.Simultaneous consideration of multiple candidate protein biomarkers for long-term risk for cardiovascular events.Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.Simplified Predictive Instrument to Rule Out Acute Coronary Syndromes in a High-Risk Population.Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction.Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with InSerious infection after acute myocardial infarction: incidence, clinical features, and outcomesRepresentation of women in randomized clinical trials of cardiovascular disease prevention.Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery.Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years.Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial.Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.The impact of postrandomization crossover of therapy in acute coronary syndromes care.Predictors of mortality and morbidity in patients with chronic heart failure.Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.International variation in and factors associated with hospital readmission after myocardial infarction.Pooled analysis of adverse event collection from 4 acute coronary syndrome trials.Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events.A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).Association of standard clinical and laboratory variables with red blood cell distribution width.Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes.Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial.Predictors of hospital mortality in the global registry of acute coronary events.Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis.Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb.Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY.Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).
P50
Q22242088-1C579B94-D28A-4D00-9E0F-86ADDAB94905Q28221803-F77F18FA-2C06-420C-BB98-B19C3B4FD57BQ28279955-3F64EBDF-D26A-449C-9E2C-2E94DD307EE5Q31054764-0F64FEFD-6FAB-4DD7-B01C-A71B65E3F837Q33246478-4F1C2CED-6D25-492A-802A-A79843D7FC46Q33295101-8377EE86-64CE-4405-BD7C-97F83FEAF5C4Q34145163-D4B4BD0B-287D-475B-A411-54FA93DF1253Q34356025-FEC802C7-3983-42D3-A664-89CD84470887Q34441146-0184A49C-E695-4002-935D-924801091CFFQ34706540-CD4F44E1-030D-48F5-87BC-4BF6B9661197Q35102374-68938D8A-B1BF-4C1F-B017-5A0BEA3AE048Q36608168-6451A5A0-5C44-45E8-878D-EFC2096F52F9Q36836398-C7C082B9-EF53-49CE-9AD2-1E11088B79F5Q37076076-6C05B3FD-D6D3-45F5-B26C-85DDAFD558A3Q37102979-B6AD6FD1-CD8E-479F-A3AB-CE8ACF6C161EQ37319863-B15E19E0-59C1-459A-A05F-CEB94B485393Q37442453-4A7AC979-A96E-4F1D-9EE3-9C3CFA617FA9Q37693535-7D72E982-6509-4761-BAF7-82A8B11BA9FCQ37838146-44A0F152-A090-4C75-B322-D1A9AB9F8B5BQ37985105-9F0EB135-018A-467B-91C1-2C609849B9CEQ38470392-4ACA49F0-7E3F-40B0-ADD6-DF21C6DEE648Q38477257-0D0FFE36-A042-4E8F-8BCB-246CC79E0825Q38488866-C46D0B1B-9C99-489B-A989-05758288897FQ38494900-EC0188DA-4D24-4D04-97B5-AE7DDECFB8ECQ39361079-0F083A17-ED4C-4773-A6C5-60DEFB3D7127Q39458892-D50F7025-F607-4E4A-9223-8DD9D524434BQ39668127-FCBE65E5-5880-4114-B2AE-7FF002CBF357Q39904589-5C886913-3989-43DE-9FFB-871D59C7534CQ39977385-F5BA3C9E-F407-4FD2-B92E-11250947845DQ40349752-8A762F0B-1D6A-4F84-9454-9779F1C7629CQ40615288-09265740-0769-4132-B0E9-480A33E3F360Q40843415-9FBFC428-2249-4CA6-BF6C-37C3CBA9A501Q40884710-AFBE2FD2-A91A-461E-9D69-20B4C062AE28Q41975659-E058B8A6-E312-49D4-B447-9FF29AC9858AQ42611826-242898AB-A57B-48B7-9A3B-48CFC4126CB5Q42624671-1BEFC803-5C5F-48FE-A89A-FA18BA680ABBQ42648046-2B9017BA-8C3B-426B-863D-B9A484A662E5Q42781494-4F26068F-D328-44C5-BCDC-4A6475A58E1FQ43078724-5919B5A6-DE0F-46FC-833C-7DA5EA2DBE5DQ43247857-7718B362-2254-442E-A347-90800C722E13
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Karen S Pieper
@ast
Karen S Pieper
@en
Karen S Pieper
@es
Karen S Pieper
@nl
type
label
Karen S Pieper
@ast
Karen S Pieper
@en
Karen S Pieper
@es
Karen S Pieper
@nl
prefLabel
Karen S Pieper
@ast
Karen S Pieper
@en
Karen S Pieper
@es
Karen S Pieper
@nl
P106
P21
P31
P496
0000-0003-4190-8341